Given these findings, particularly in the very high-risk TP53-mutant group, three phase 3 trials opened which are comparing magrolimab/AZA versus AZA in patients with untreated intermediate- to very high-risk MDS (NCT04313881), magrolimab/AZA versus AZA/VEN or intensive chemotherapy in patients with untreated TP53-mutant AML (NCT04778397), and magrolimab/AZA/VEN versus AZA/VEN in patients with untreated AML who are ineligible for standard intensive chemotherapy (NCT05079230). This evidence concerns the gene TP53 and acute myeloid leukemia.